And then in late May: MONMOUTH JUNCTION, N.J.
Post# of 154945
(Total Views: 337)
Posted On: 07/01/2025 11:10:22 PM
And then in late May:
MONMOUTH JUNCTION, N.J., May 30, 2025 /PRNewswire/ -- Creatv Bio, a Division of Creatv MicroTech, Inc. ("Creatv"
in collaboration with CytoDyn Inc. ("CytoDyn" presents promising four-year survival rates from a pooled clinical trial analysis of patients with metastatic triple-negative breast cancer ("mTNBC" treated with leronlimab and PD-L1 immune checkpoint inhibitors ("ICI". Leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, was tested with and without ICIs in n=28 mTNBC patients. Results indicated that leronlimab treatment correlated with increased expression of PD-L1 on circulating tumor associated cells, as measured using the LifeTracDx® blood test from Creatv. The analysis also revealed promising survival observations among patients who experienced a significant increase in PD-L1 expression and subsequently pursued treatment with an ICI. Four year follow-up results were presented at the ESMO Breast Cancer meeting on May 15, 2025 by Dr. Richard Pestell, available here.
The LifeTracDx® is a universal cancer blood test that uses both circulating tumor cells (CTCs) and Cancer Associated Macrophage-Like (CAML) cells, macrophages that engulf tumor cells, as sensitive and accurate markers for real-time monitoring of tumor response in cancer patients. In the trials presented at ESMO, results showed that monitoring the expressions of PD-L1 before and after induction of leronlimab using the LifeTracDx® blood test identified upregulation of PD-L1 expression in 76% of patients after therapy induction. In a 4-year overall survival follow-up, 5 of the patients with upregulated PD-L1 detected by LifeTracDx® blood test and treated with the ICIs atezolizumab or pembrolizumab were alive after four years.
I expect we will kick some arse in our current trial. Absolutely no doubt that we will be able to steer the treatment where it needs to go once all the blood test get analyzed.
MONMOUTH JUNCTION, N.J., May 30, 2025 /PRNewswire/ -- Creatv Bio, a Division of Creatv MicroTech, Inc. ("Creatv"
in collaboration with CytoDyn Inc. ("CytoDyn" presents promising four-year survival rates from a pooled clinical trial analysis of patients with metastatic triple-negative breast cancer ("mTNBC" treated with leronlimab and PD-L1 immune checkpoint inhibitors ("ICI". Leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, was tested with and without ICIs in n=28 mTNBC patients. Results indicated that leronlimab treatment correlated with increased expression of PD-L1 on circulating tumor associated cells, as measured using the LifeTracDx® blood test from Creatv. The analysis also revealed promising survival observations among patients who experienced a significant increase in PD-L1 expression and subsequently pursued treatment with an ICI. Four year follow-up results were presented at the ESMO Breast Cancer meeting on May 15, 2025 by Dr. Richard Pestell, available here. The LifeTracDx® is a universal cancer blood test that uses both circulating tumor cells (CTCs) and Cancer Associated Macrophage-Like (CAML) cells, macrophages that engulf tumor cells, as sensitive and accurate markers for real-time monitoring of tumor response in cancer patients. In the trials presented at ESMO, results showed that monitoring the expressions of PD-L1 before and after induction of leronlimab using the LifeTracDx® blood test identified upregulation of PD-L1 expression in 76% of patients after therapy induction. In a 4-year overall survival follow-up, 5 of the patients with upregulated PD-L1 detected by LifeTracDx® blood test and treated with the ICIs atezolizumab or pembrolizumab were alive after four years.
I expect we will kick some arse in our current trial. Absolutely no doubt that we will be able to steer the treatment where it needs to go once all the blood test get analyzed.
(7)
(0)